Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. is a U.S.-based dermatology company focused on developing and commercializing prescription therapies for skin diseases. Its commercial product, YCANTH (VP-102), is a physician-administered topical treatment, and the company also has pipeline programs in common warts and basal cell carcinoma.

−33,9 %

−50,3 %

+370,2 %

2.59

2.45

— Verrica Pharmaceuticals Inc.
%
Commercial dermatology product100% YCANTH (VP-102) is the company's marketed, physician-administered topical therapy.
Access and distribution services0% YCANTH-Rx and pharmacy/wholesaler channels support prescription fulfillment and access.
Clinical development pipeline0% Development programs for common warts and basal cell carcinoma extend the product platform.

The company sells primarily to pharmaceutical wholesalers and distributors, which then supply pharmacies, clinics,...

  • Pharmaceutical wholesalers/distributorsprimary

    Buy YCANTH and distribute it onward to pharmacies, clinics, hospitals, and federal healthcare programs.

  • Pediatric dermatologistsprimary

    Prescribe YCANTH for pediatric molluscum contagiosum and are the core clinical audience.

  • Dermatologistsprimary

    Use YCANTH in dermatology practices and represent a major physician adoption segment.

  • Pediatricians and select primary care HCPssecondary

    Help broaden access to treatment beyond specialist dermatology settings.

  • Payers and government programsprimary

    Commercial, Medicaid, and managed Medicaid plans influence coverage and patient access.

Verrica's commercial business is concentrated in the United States, where YCANTH is marketed and shipped...

  • •United States is the core commercial market for YCANTH
  • •U.S. physician sales force targets dermatology and pediatric practices
  • •Japan is covered through Torii's exclusive license for cantharidin products
  • •Raw cantharidin sourcing has exposure to suppliers in China
  • •Commercial access depends on U.S. payer and pharmacy channels

Verrica's strategy centers on expanding YCANTH adoption in the U.S. through physician education, consumer awareness,...

01
Grow YCANTH adoption in the U.S.short-term

The commercial product is the main source of revenue and brand recognition.

02
Secure and maintain reimbursement accessshort-term

Coverage determines whether physicians and patients can obtain the product efficiently.

03
Advance pipeline indicationsmedium-term

Additional approved uses could diversify revenue beyond molluscum contagiosum.

04
Expand geographic reach through partnersmedium-term

Licensing can extend the platform without building a full international commercial infrastructure.

The company depends on a single commercial product and on successful reimbursement, physician adoption, and supply...

critical

Going-concern and financing risk

The company expects to need additional capital to fund commercialization and R&D.

Scope
Operations and pipeline funding
Materiality
high
high

Single-product concentration

YCANTH is the only commercial product, so demand changes flow directly into revenue.

Scope
Revenue and cash flow
Materiality
high
high

Gross-to-net and returns risk

Rebates, chargebacks, discounts, and returns can reduce reported net sales.

Scope
Product revenue, net
Materiality
high
high

Clinical and regulatory risk

Pipeline programs need successful trials and FDA approvals before they can contribute revenue.

Scope
VP-102 common warts, VP-315 BCC
Materiality
high
high

Supply-chain concentration

Raw cantharidin is sourced directly or indirectly from suppliers in China.

Scope
API and finished product supply
Materiality
high
medium

Competitive pressure

YCANTH competes with OTC products, procedures, off-label therapies, and future entrants.

Scope
Dermatology treatment market
Materiality
medium
ASC 606 revenue recognition and gross-to-net reserves
Can materially affect quarterly revenue and margins
Inventory and cost of product revenue
Can distort period-to-period gross margin comparability
Going-concern assessment
Important for assessing balance-sheet and funding risk

VERTEX PHARMACEUTICALS INC / MA

VRTX · Pharmaceutical Preparations

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

VERU INC.

VERU · Pharmaceutical Preparations

Journey Medical Corp

DERM · Pharmaceutical Preparations

Viridian Therapeutics, Inc.\DE

VRDN · Pharmaceutical Preparations

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

: 29.4.2026